Competency in menopause management: Whither goest the internist?

Journal of Women's Health

Volumn 23, Issue 4, 2014, Pages 281-285

  Santen, Richard J ^a   Stuenkel, Cynthia A ^b   Burger, Henry G ^c   Manson, Joann E ^d  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MONASH UNIVERSITY   (Australia)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL COMPETENCE; CONSENSUS; HUMAN; INTERNIST; MENOPAUSE; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WOMEN'S HEALTH;

CLINICAL COMPETENCE; EDUCATION, MEDICAL, CONTINUING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNAL MEDICINE; MENOPAUSE; PHYSICIAN'S ROLE; PRIMARY HEALTH CARE; RISK;

EID: 84898010617     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2014.4746     Document Type: Review

References (50)

1. Carr BR, Wilson JD. Disorders of the ovary and female reproductive tract. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine, 13th ed. New York: McGraw-Hill, 1994: 2016-2017.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
3. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of U.S. office-based physicians, 2000-2009. Menopause 2011;18:385-392.
4. Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann N Y Acad Sci 2010;1205:268-276.
5. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and populationbased evidence. J Clin Oncol 2006;24:e49-e50.
6. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. New Engl J Med 2007;356:1670-1674.
7. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA; National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99: 1335-1339. [Erratum in J Natl Cancer Inst 2007;99:1493.]
8. Sprague BL, Trentham-Dietz A, Remington PL. The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control 2011;22:125-134.
9. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:Sl-S66.
10. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
11. Pines A. Guidelines and recommendations on hormone therapy in the menopause. J Midlife Health 2010;1:41-42.
12. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477. [Erratum appears in JAMA. 2008;299:1426.]
13. Manson JE, Allison MA, Rossouw JE et al. Estrogen therapy and coronary-artery calcification. New Engl J Med 2007;356:2591-2602.
14. Fournier A. Estrogen-progestagen menopausal homone therapy and breast cancer: Does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138-5143.
15. Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013;121: 172-176.
16. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the-Women's Health Initiative randomized trials. JAMA 2013; 310:1353-1368.
17. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: An individual patient pooled analysis. Journal of Clinical Oncology 2009;27: 2831-2837.
18. Komm BS, Mirkin S. Evolution of the tissue selective estrogen complex (TSEC). J Cell Physiol 2013;228:1423-1427.
19. Simon JA, Lin VH, Radovich C, Bachmann GA; Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418-427.
20. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. New Engl J Med 2008;359:697-708.
21. Lobo RA. Menopause and aging. In: Strauss JF, Barbieri RL, eds. Yen and Jaffe's reproductive endocrinology, 6th ed. Philadelphia: Elsevier, 2009:325-355.
22. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: Toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-414.
23. Prentice RL,Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
24. Pines A, Sturdee DW, Birkhauser MH, et al. HRT in the early menopause: Scientific evidence and common perceptions. Climacteric 2008;11:267-272.
25. Birkhauser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri-and postmenopause. Climacteric 2008;11:108-123.
26. Stuenkel CA, Gass ML, Manson JE, et al. A decade after the Women's Health Initiative-the experts do agree. Menopause 2012;19:846-847.
27. Gass ML. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2012; 19;257-271.
28. Moyer VA; U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
29. Sturdee DW, Pines A; International Menopause Society Writing Group, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-320.
30. Pai JK, Manson JE. Acceleration of cardiovascular risk during the late menopausal transition. Menopause 2013;20:1-2.
31. Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism 2013;62:S15-19.
32. Eaton CB, Abdulbaki AM, Margolis KL, et al. Racial and ethnic differences in incident hospitalized heart failure in postmenopausal women: The Women's Health Initiative. Circulation 2012;126:688-696.
33. Cook NR, Paynter NP, Eaton CB, et al. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation 2012;125:1748-1756.
34. Cauley JA, Danielson ME, Boudreau R, et al. Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: The Women's Health Initiative (WHI). J Bone Mineral Res 2011;26:2378-2388.
35. Irwin ML, McTiernan A, Manson JE, et al. Physical activity and survival in postmenopausal women with breast cancer: Results from the women's health initiative. Cancer Prevention Research 2011;4:522-529.
36. Kim HC, Greenland P, Rossouw JE, et al. Multimarker prediction of coronary heart disease risk: The Women's Health Initiative. J Am College Cardiol 2010;55:2080-2091.
37. Bassuk SS, Manson JE. Menopausal hormone therapy and cardiovascular disease risk: Utility of biomarkers and clinical factors for risk stratification. Clin Chem 2014;60: 68-77.
38. Spencer AL, Bost JE, McNeil M. Do Women's health internal medicine residency tracks make a difference? J Womens Health 2007;16:1219-1223.
39. Pancholy AB, Goldenhar L, Fellner AN, Crisp C, Kleeman S, Pauls R. Resident education and training in female sexuality: Results of a national survey. J Sex Med 2011;8:361-366.
40. Dixon JG, Bognar BA, Keyserling TC, et al. Teaching women's health skills: Confidence, attitudes and practice patterns of academic generalist physician. J Gen Intern Med 2003;18:411-418.
41. Steiner AZ, Fritz M, Sites CK, Coutifaris C, Carr BR, Barnhart K. Resident experience on reproductive endocrinology and infertility rotations and perceived knowledge. Obstet Gynecol 2011; 117:324-330.
42. Christianson MS. Menopause Education: Needs assessment of American obstetrics and gynecology residents. Menopause 2013;20:1120-1125.
43. Lenfant F, Tremollieres F, Gourdy P, Arnal JF. Timing of the vascular actions of estrogens in experimental and human studies: Why protective early, and not when delayed? Maturitas 2011;68:165-173.
44. Mendelsohn ME. Estrogen actions in the cardiovascular system. Climacteric 2009;12(Suppl1):18-21.
45. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-1292.
46. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66:295-306.
47. Joakimsen O, Bonaa KH, Stensland-Bugge E, Jacobsen BK. Age and sex differences in the distribution and ultrasound morphology of carotid atherosclerosis: The Tromso Study. Arterioscler Thromb Vasc Biol 1999;19:3007-3013.
48. Clarkson TB. Can women be identified that will derive considerable cardiovascular benefits from postmenopausal estrogen therapy? J Clin Endocrinol Metab 2008;93:37-39.
49. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587.
50. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.